Whitehawk Therapeutics, Inc. (WHWK)

Whitehawk Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing antibody-drug conjugates for cancer. The company was formerly Aadi Bioscience. It took its current name after selling its previously marketed drug and moving its strategy to a new pipeline of oncology programs.

Antibody-drug conjugates combine an antibody that targets a protein found on tumor cells with a potent cytotoxic payload, so the payload can be delivered selectively to cancer cells. Whitehawk's candidates are aimed at tumor targets in several solid cancers. They were in-licensed from partners that hold the underlying conjugation and manufacturing technologies.

The company's common stock trades on the Nasdaq under the ticker WHWK.